Symposium 1: World Congress of Virus and Infections

Track 1: Global Epidemics and Prevention
Track 1-1: Molecular Epidemiology of Emerging Virus Transmission and Distribution
Track 1-2: Molecular Epidemiology: Zoonoses, Recombination, and Co-infection
Track 1-3: Prevention and Prevention Interventions
Track 1-4: Human Resources, Infrastructure and Health Care Strengthening
Track 1-5: Operational Research in Prevention, Care, and Treatment
Track 1-6: Impact and Integration of Programmes

Track 2: General Virology and Basic Sciences
Track 2-1: Viruses from Structure to Biology
Track 2-2: Viral Genetics of Pathogen Transmission
Track 2-3: Viral Genomics and Proteomics
Track 2-4: Viral Replication Cycle
Track 2-5: Viral Tropism and Transmission
Track 2-6: Cellular Factors Affecting Viral Replication and Pathogenicity
Track 2-7: Physical Virology

Track 3: Medical and Clinical Virology
Track 3-1: Clinical Viral Diagnostics
Track 3-2: Emerging and Zoonotic infections
Track 3-3: Vector and Blood Borne Diseases
Track 3-4: Viral Infections of the CNS
Track 3-5: Viral Gastroenteritis

Track 4: Retrovirus-HIV/AIDS-Basic Sciences and Implications
Track 4-1: Entry
Track 4-2: Post-Entry
Track 4-3: Assembly / Release
Track 4-4: Integration
Track 4-5: Reverse Transcription / Recombination
Track 4-6: Pathogenesis / Host Factors
Track 4-7: Restriction Factors II
Track 4-8: Transcription/Processing/Export/Translation
Track 4-9: Packaging
Track 4-10: Accessory Proteins
Track 4-11: Immunology of HIV Infection
Track 4-12: Viral Diversity and Bioinformatics
Track 4-13: War and Peace between Viruses: Interactions of HIV with co-infecting viruses as Determinants of HIV Disease Progression
Track 4-14: Diagnostics and Prognostics of HIV Infections
Track 4-15: Field Trials of Diagnosis and Monitoring Tools
Track 4-16: HIV-Associated Diseases
Track 4-17: Antiretroviral Therapies and Resistances
Track 4-18: Children and Adolescents-specific Issues
Track 4-19: Complications of Therapy and Adherence
Track 4-20: Biomedical Prevention -Prevention of Mother-to-Child Transmission
Track 4-21: Microbicide Research
Track 4-22: Preventive Vaccine Clinical Trials
Track 4-23: AIDS Vaccines-New Approaches

Track 5: Other Retrovirus Researches
Track 5-1: Alpharetrovirus
Track 5-2: Betaretrovirus
Track 5-3: Gammaretrovirus
Track 5-4: Deltaretrovirus- Bovine Leukaemia Virus
Track 5-5: Human T-lymphotropic Virus
Track 5-6: Epsilonretrovirus
Track 5-7: Simian Virus and Feline Immunodeficiency Viruses
Track 5-8: Spumavirus

Track 6: Respiratory and Emerging/Re-emerging Viruses
Track 6-1: Avian Flu H5N1
Track 6-2: Severe Acute Respiratory Syndrome (SARS) and Other Severe Viral Pneumonia
Track 6-3: Dengue Virus
Track 6-4: Herpes Viruses and Poxviruses
Track 6-5: RSV
Track 6-6: West Nile Virus
Track 6-7: Hantaviruses
Track 6-8: Filoviruses- Ebola virus
Track 6-9: Japanese Encephalitis
Track 6-10: Influenza A (H1N1) Virus

Track 7: Neuro-Viorology
Track 7-1: Mechanisms of Viral Neuropathogenesis
Track 7-2: NeuroAIDS Complications
Track 7-3: Aging and Metabolic Syndromes of Neurologic Disorders by Viruses
Track 7-4: Molecular diagnosis of CNS Viral infections

Track 8: Pediatric Viral Infectious Diseases
Track 8-1: Viral Skin Infections, Prevention and Treatment
Track 8-2: Respiratory Syncytial Virus Infection –Prevention
Track 8-3: Rotavirus Vaccine and Children Diarrheal Prevention and Treatment
Track 8-4: Mouth and Hand Virus Infection and Management
Track 8-5: Other Virus Infections in Children and Management

Track 9: Human Tumor Virology
Track 9-1: Tumor Virology and Immunology
Track 9-2: Polyomavirus Infections Associated Cancer
Track 9-3: HPV Infection Associated Cervical Cancer
Track 9-4: Human Herpes Virus 8 in Kaposi-Sarcoma
Track 9-5: Epstein - Barr Virus and Cancers
Track 9-6: Human T Cell Leukemia Virus Type 1
Track 9-7: Simian Virus 40 in Cancers
Track 9-8: HIV Associated Squamous Cell Cancer
Track 9-9: Avian Leucosis Virus and Cancers

Track 10: Viral Immunology, Infection and Immunity
Track 10-1: Pathogenesis, Humoral Responses and Immune Receptor Diversification
Track 10-2: Innate Immunity & Specific Immunity
Track 10-3: Mucosal Immunity
Track 10-4: Neutralization and Evolution of Viral Antigens
Track 10-5: Types of Virus-specific Antibodies
Track 10-6: Specificity of Test Methods
Track 10-7: Cell-Mediated Immunity and Antibody-dependent Cell-mediated Cytotoxicity
Track 10-8: Natural Killer (NK) cells
Track 10-9: RNAi in Immunity Research

Track 11: Agriculture and Plant Virology
Track 11-1: Wheat and Rice Virus
Track 11-2: Tobacco Virus and the Economic Implications
Track 11-3: Potato and Bean Virus
Track 11-4: Other Vegetable Virus
Track 11-5: The Plant Virus Biodiversity, Ecology and Molecular Virology
Track 11-6: Viral Counter-defense Proteins
Track 11-7: Tospoviruses
Track 11-8: RNAi in Plant Virus
Track 11-9: Viral Pathogen and Plant Disease Control
Track 11-10: Plant Virus' Contributions to Green Biotech Products

Track 12: Veterinary Virology
Track 12-1: Viral Molecular Diagnosis and Diseases Control
Track 12-2: Animal Vaccines and Viral Immunology
Track 12-3: Host-virus interactions and pathogenesis and Prion Disease
Track 12-4: Emerging Viruses and Zoonoses Epidemiology
Track 12-5: Veterinary Viral Functional Genomics and Proteomics

Symposium 2: Inaugurate Symposium of Hepatitis Virus

Track 1: Hepatisis C Virus
Track 1-1: Hepatitis C: Basic Virology & Immunology
Track 1-2: Hepatitis C Clinical Course and Therapy
Track 1-3: HCV Virology
Track 1-4: HCV Quasispecies & Kinetics
Track 1-5: Natural History of Hepatitis C
Track 1-6: New Agents for Hepatitis C Clinical
Track 1-7: HCV Immunology & Vaccines
Track 1-8: HCV Epidemiology
Track 1-9: Immunology of HCV Infection
Track 1-10: HCV Cell Biology & Antiviral Effects
Track 1-11: New Therapies for Hepatitis C: Preclinical
Track 1-12: Therapy of Hepatitis C: Current Issues
Track 1-13: HIV Co-infection (HBV & HCV)

Track 2: Hepatitis B and D Virus
Track 2-1: Hepatitis B and D: Basic Virology & Immunology
Track 2-2: Hepatitis B Therapy (I)
Track 2-3: HBV Virology
Track 2-4: Latent & Occult HBV Infection
Track 2-5: HBV Therapy (I)
Track 2-6: HBV Epidemiology
Track 2-7: Issues in Control of HBV
Track 2-8: HBV Virology
Track 2-9: HBV Immunology
Track 2-10: HBV Vaccine & Prevention
Track 2-11: Other Hepatitis
Track 2-12: Antiviral Resistance & HBV
Track 2-13: Experimental Approaches to Therapy of HBV
Track 2-14: Natural History of HBV

Track 3: Hepatitis A and E Virus
Track 3-1: Hepatitis A Virus and Hepatitis E Virus
Track 3-2: Global Control of Viral Hepatitis
Track 3-3: HAV Virology
Track 3-4: HEV Virology
Track 3-5: HEV Pathogenesis
Track 3-6: HEV Epidemiology
Track 3-6: HAV Epidemiology

Track 4: Virus and Liver Cancer
Track 4-1: Hepatocellular Carcinoma (HCC)
Track 4-2: Epidemiology of HCC
Track 4-3: Biomarkers for HCC
Track 4-4: Therapy of HCC

Symposium 3: World Summit of Antivirals

Track 1: Targeting Drug Discovery and Development-Small Molecules
Track 1-1: Targeting Entry of HIV
Track 1-2: Transcriptase Inhibitors and DNA Polymerase Inhibitors
Track 1-3: Protease Inhibitors
Track 1-4: Targeting Assembly / Release
Track 1-5: Targeting Integrase by Inhibitors
Track 1-6: Targeting Reverse Transcription / Recombination
Track 1-7: Targeting Cytokines and Protein Kinases
Track 1-8: Targeting Transcription/Processing/Export/Translation
Track 1-9: Anti Influenza, Avian Flu, and SARS Drug Discovery
Track 1-10: Hepatitis Virus Small Molecule Drug Development
Track 1-11: New HIV Chemotherapeutics Development
Track 1-12: Nanotechnology and Delivery Technologies for Antivirals

Track 2: Antiviral Vaccine Development
Track 2-1: Cytomegalovirus Vaccines
Track 2-2: Dengue Vaccines
Track 2-3: Hepatitis B-Emergent Bio-Solutions
Track 2-4: HCV Vaccines
Track 2-5: Herpes Simplex Virus Vaccines
Track 2-6: Human Papilloma virus (HPV)
Track 2-7: Influenza Vaccines
Track 2-8: Respiratory Syncytial Virus Vaccines
Track 2-9: West Nile Virus Vaccines
Track 2-10: Other Emerging Infectious Disease Vaccines

Track 3: Imunotherapy and Therapeutic Antibodies
Track 3-1: Novel Immune-based Therapies
Track 3-2: Recombinant Simian Glycosylated Interleukin-7 Prevents
Track 3-3: Toll-like Receptor-7 Signaling and Interferon
Track 3-4: Therapeutic Expression of Fusion Inhibitory C Peptides
Track 3-5: Immune Therapies Involving Interleukin-2
Track 3-6: Immune Stimulatory Capacity of Dendritic Cells
Track 3-7: Interleukin-2 Adjuvant Therapy
Track 3-8: Monoclonal Antibodies against HCV
Track 3-9: Monoclonal Antibodies against Herpes Virus
Track 3-10: Monoclonal Antibodies against Human Immunodeficiency Virus (HIV)

Track 4: Gene Therapy for Viral Infections
Track 4-1: RNAi Applications in HIV/AIDS
Track 4-2: Viral Vectors for Gene Therapy
Track 4-3: Targeting CXCR4 with siRNA
Track 4-4: Antisense Oligodeoxynucleotide
Track 4-5: DNA Vaccines on Viral Infections
Track 4-6: Genetic Vaccines for Other Viral Infection